Stockreport

Precipio Pathology Sales Metrics Demonstrate Continuous Improvement in Q2 2019

Precipio, Inc.  (PRPO) 
US:NASDAQ Investor Relations: precipiodx.com/investors.html
PDF NEW HAVEN, Conn., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the results of three key perfor [Read more]